Collegium Pharmaceutical/$COLL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Collegium Pharmaceutical

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Ticker

$COLL
Primary listing

Industry

Pharmaceuticals

Employees

357

ISIN

US19459J1043

COLL Metrics

BasicAdvanced
$961M
23.83
$1.25
0.63
-

What the Analysts think about COLL

Analyst ratings (Buy, Hold, Sell) for Collegium Pharmaceutical stock.

Bulls say / Bears say

Collegium Pharmaceutical reported Q1 2025 revenue of $177.8 million, a 22.7% year-over-year increase, surpassing analyst expectations. (thepilotnews.com)
Analysts maintain a bullish outlook, with Needham's Serge Belanger reiterating a 'Buy' rating and a $46.00 price target as of April 2025. (benzinga.com)
Institutional investors like Raymond James Financial Inc. have increased their holdings, investing $2.43 million in Collegium Pharmaceutical as of March 2025. (etfdailynews.com)
Collegium's operating margin declined to 12.2% in Q1 2025 from 34.1% the previous year, indicating increased operational costs. (thepilotnews.com)
AllianceBernstein L.P. reduced its stake in Collegium Pharmaceutical, signaling potential concerns about the company's future performance. (americanbankingnews.com)
StockNews.com downgraded Collegium Pharmaceutical from a 'Strong Buy' to a 'Buy' rating in April 2025, suggesting a less optimistic outlook. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.

COLL Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

COLL Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $COLL

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs